Presentation, Treatment, and Outcomes of Dural Metastases in Men with Metastatic Castrate-Resistant Prostate Cancer: A Case Series

Abstract Purpose: Men with metastatic castrate-resistant prostate cancer (mCRPC) have shown increased survival since the introduction of docetaxel-based chemotherapy in 2004. While bone metastases are common in prostate cancer, cranial dural metastases (DM) are not. We hypothesize that longer survival in patients with mCRPC may increase the incidence of uncommon metastatic sites, including the cranial dura. We describe 10 cases of DM in men with mCRPC and review the relevant literature. Materials and Methods: We conducted a retrospective chart review of 10 subjects with mCRPC, diagnosed ante-mortem with DM at our institution between August 1, 2003 and June 1, 2008. Variables analyzed included prognostic factors at prostate cancer diagnosis, number of therapies prior to DM, treatments administered for DM with response achieved, and survival following diagnosis of DM. Results: Median age at prostate cancer diagnosis was 59 years (range, 52–80), with a median Gleason's score of 9 (range, 8–10) and prostate-s...